Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab Extension in Chronic Non-infectious Uveitis (EYEGUARD-X)
NCT02375685Phase 3Terminated
- Sponsor
- Servier
- Start
- Aug 2014
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of gevokizumab in chronic non-infectious uveitis, sponsored by Servier. Started Aug 2014; status: terminated.
02
Drugs
gevokizumab
03
Conditions
chronic non-infectious uveitis
Beyond the preview
Go deeper on NCT02375685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375685.